Skip to main content
. 2023 Nov 29;21(12):624. doi: 10.3390/md21120624

Figure 4.

Figure 4

Reduction of serum lipid, subcutaneous, and visceral fat content in HFD-fed mice by laminarin. C57BL/6J mice were fed either a ND or a HFD for 14 weeks before randomly divided into seven groups: ND, control group; HFD, control group; HFD, ezetimibe group (10 mg/kg/day) and HFD high-dose (200 mg/kg/day); HFD medium-dose (100 mg/kg/day); HFD low-dose (50 mg/kg/day) laminarin; and HFD drug combination group (ezetimibe: 10 mg/kg/day and laminarin: 100 mg/kg/day). (A–D) Concentrations of serum lipids, including (A) total cholesterol (TC, mM, n = 12); (B) total triglyceride (TG, mM, n = 12); (C) LDL-C (mM, n = 12); and (D) HDL-C (mM, n = 12). (E) Inhibitory effect of laminarin on subcutaneous and visceral fat content. The data in the bar graph are expressed as mean ± SD. Significant differences compared with the HFD-control mice are indicated as * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, n.s., no significance.